# Aligos Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Aligos Therapeutics, Inc.).

## Overview

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies for liver diseases and viral infections. Its core programs target chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. The company’s pipeline includes pevifoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections, alongside preclinical oligonucleotide programs. Aligos is still pre-commercial, so its business is centered on research, clinical development, external funding, and potential future partnerships rather than product sales.

## Products & services

• Pevifoscorvir sodium for chronic HBV infection
• ALG-055009 for MASH and obesity
• ALG-097558 for coronavirus infections
• Oligonucleotide platform with siRNA and ASO programs
• Licensed BNA and GalNAc delivery chemistries
• Preclinical liver and viral disease programs

- **Clinical-stage drug candidates** (0%) — Lead therapeutic programs in HBV, MASH/obesity, and coronavirus infections that are being advanced through preclinical and clinical development.
- **Oligonucleotide platform** (0%) — siRNA and ASO-based discovery and development capabilities used to create liver-targeted antiviral and metabolic disease therapies.
- **Licensed enabling technologies** (0%) — Proprietary BNA and GalNAc chemistries licensed to improve potency, pharmacokinetics, and liver delivery.
- **Collaboration and contract revenue** (100%) — Revenue from research and development services and prior collaboration arrangements while the pipeline remains pre-commercial.

- Pevifoscorvir sodium (ALG-000184) for chronic HBV infection
- ALG-055009 for MASH and obesity
- ALG-097558 for coronavirus infections
- siRNA and antisense oligonucleotide (ASO) programs
- Third-generation bridged nucleic acid (BNA) chemistry
- GalNAc-enabled liver-targeting delivery technologies
- Preclinical programs in liver disease and viral infections

## Customers

Aligos does not sell approved medicines, so its current revenue comes from collaboration agreements and third-party research and development contracts rather than end-market product customers. Its primary economic counterparties are pharmaceutical collaborators, government funders, and research partners that support specific programs such as coronavirus development. The eventual commercial customers, if products are approved, would be physicians, hospitals, and specialty prescribers treating liver disease and viral infections. In the near term, the company’s customer base is therefore concentrated in funding partners and development collaborators that help finance and de-risk its pipeline.

- **Collaboration partners** (primary) — Pharma and biotech partners that provide upfront, milestone, or shared-development funding for pipeline programs.
- **Government and public health funders** (primary) — NIH, NIAID, and related agencies funding coronavirus studies and other externally supported research.
- **Contract research customers** (secondary) — Third parties purchasing R&D services that generate contract revenue while the company remains pre-commercial.
- **Future specialty healthcare providers** (emerging) — Hepatologists, infectious disease specialists, and treatment centers that would prescribe approved therapies if development succeeds.

- Pharmaceutical collaborators that fund or co-develop pipeline assets
- Government agencies and public health funders supporting coronavirus work
- Research partners and contract customers buying R&D services
- Future specialty prescribers treating chronic HBV and liver disease
- Future hepatology and infectious disease treatment centers

## Geography

Aligos is headquartered in the United States and its business is primarily managed from there. The company’s current development footprint is global in nature because its clinical and nonclinical work can involve U.S. government funding, U.K.-supported platform trials, and external contractors. Its coronavirus program has been supported by NIH/NIAID funding in the United States and by the AGILE platform trial in the United Kingdom. Because the company is pre-commercial, geography matters more for where research is funded and conducted than for where products are sold.

- United States is the company’s home market and operating base
- NIH/NIAID funding supports U.S.-based coronavirus research
- United Kingdom platform-trial activity supports ALG-097558 development
- Clinical and nonclinical work is outsourced across specialized vendors
- No meaningful commercial geography yet because assets are pre-commercial

## Strategy

Aligos’ strategy is to advance a small number of differentiated, potentially best-in-class drug candidates in liver disease and viral infections. The company is prioritizing chronic HBV, MASH/obesity, and coronavirus programs where it believes its chemistry and delivery platform can create clinical differentiation. It is also using external funding, government grants, and collaborations to reduce the capital burden of development, especially for ALG-097558. Longer term, the company may commercialize selectively on its own or partner with larger pharmaceutical companies to expand reach and reduce execution risk.

- **Advance pevifoscorvir sodium in chronic HBV** (medium-term) — HBV is a core value driver and a major unmet medical need where clinical success could validate the platform.
- **Progress ALG-055009 in MASH and obesity** (medium-term) — This expands the pipeline into a large metabolic disease market and diversifies the company beyond antivirals.
- **Leverage public funding for coronavirus programs** (short-term) — External funding lowers cash burn and supports continued development of ALG-097558 without relying solely on equity capital.
- **Preserve optionality through partnerships** (medium-term) — Collaborations can provide capital, development expertise, and commercialization access for a pre-commercial biotech.

- Advance lead assets through clinical proof-of-concept
- Focus on HBV, MASH/obesity, and coronavirus indications
- Use BNA and GalNAc chemistry to improve liver targeting
- Seek external funding for coronavirus development
- Pursue partnerships or licensing to extend commercial reach
- Build only limited internal commercial infrastructure until approval

## Risks

Aligos faces the classic risks of a clinical-stage biotech: no approved products, no product sales, and a long path to proving safety and efficacy in humans. The company has a limited operating history and expects continued losses, so its ability to fund development depends on future capital raises, collaborations, or external grants. Its pipeline is concentrated in a few programs, which makes setbacks in HBV, MASH, or coronavirus development especially damaging. More broadly, it also faces competition from better-funded biopharma companies, regulatory uncertainty, and the possibility that public funding or trial support for coronavirus programs could change.

- **Clinical development failure** [critical] — The company’s value depends on proving safety and efficacy for a small number of drug candidates.
- **Need for additional capital** [high] — The company expects continued losses and has stated that existing resources may not be sufficient beyond the near term.
- **Dependence on external funding and collaborations** [high] — Coronavirus development is partially funded by NIH/NIAID and platform-trial support, which may not continue.
- **Competition from larger biopharma companies** [high] — Competitors may reach approval faster, have stronger IP positions, or offer better efficacy and safety.
- **Regulatory and reimbursement uncertainty** [medium] — Even successful candidates must clear lengthy approval pathways and future pricing/reimbursement hurdles.

- No approved products means no commercial revenue base
- Clinical trial failure could eliminate value in lead programs
- Need for additional capital could force dilution or cutbacks
- Heavy reliance on third parties raises execution and cost risk
- Competition from larger biopharma firms with more resources
- Government funding dependence creates program-specific uncertainty
- Regulatory approval risk is high in liver and antiviral development

## Accounting

Aligos’ reported results are driven by judgment-heavy biotech accounting rather than product sales. Revenue is recognized from collaboration arrangements and contract R&D services over time as costs are incurred, so quarterly revenue can be lumpy and highly dependent on project activity and contract timing. A major accounting estimate is accrued research and development expense, which requires management to estimate work performed by CROs, clinical sites, and manufacturers before invoices are received. The company also records fair value changes on common warrants, which can materially affect reported net income or loss even though they do not reflect operating performance. Because the business is pre-commercial, investors should focus on how these estimates, funding arrangements, and milestone-based contracts affect comparability across periods.

- **Accrued research and development expenses** — Affects operating expenses and period-to-period comparability
- **Collaboration and contract revenue recognition** — Can create lumpy quarterly revenue and margin patterns
- **Fair value of warrants** — Can distort bottom-line results and EPS-like metrics
- **Going concern assessment** — Important for liquidity analysis and financing risk

- Collaboration revenue is recognized over time as related costs are incurred
- Contract R&D revenue depends on third-party service activity and milestones
- Accrued R&D expenses rely on estimates from CROs and vendors
- Fair value changes in common warrants can swing reported earnings
- Quarterly results may be volatile because development spending is project-based
- No product revenue yet, so operating results are dominated by R&D and G&A

---

*Last updated: 2026-08-11T04:46:19.974262+00:00*